Loading
A phase 3 trial of XZP-3287 in advanced solid tumours, run by Xuanzhu Biopharmaceutical Co., Ltd., active and no longer recruiting.
A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer is a phase 3 interventional study registered as NCT05257395 by Xuanzhu Biopharmaceutical Co., Ltd., with 397 participants enrolled, started 2022-03-14 and due to reach its primary completion in 2025-12-05. Interventions recorded: XZP-3287+ Letrozole/Anastrozole and Placebo + Letrozole/Anastrozole.
Shares XZP-3287, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Xuanzhu Biopharmaceutical and the tag pipeline.
Shares Anastrozole, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Anastrozole and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.